NCI Receives 2016 Excellence in Technology Transfer Award

The Federal Laboratory Consortium for Technology Transfer (FLC) honored NCI with two 2016 Excellence in Technology Transfer awards, which will be formally awarded in April 2016. According to the FLC, this award recognizes the work of employees of FLC member laboratories and non-laboratory staff who have accomplished outstanding work in the process of transferring federally developed technology. One of the awards was given for the project, "From Discovery to Commercialization, Monoclonal Antibody Ch14.18, Unituxin™ (dinutuximab)." The FDA approved Unituxin in 2015 after 25 years of clinical development, and a collaborative approach that utilized diverse expertise, technology, and strategies was essential to this accomplishment. The FLC award recognizes the efforts of the following individuals from industry, academia, and the federal government, including staff from the NCI's Technology Transfer Center, Frederick National Laboratory for Cancer Research, and Division of Cancer Treatment and Diagnosis:

Donna Bialozor, AACP, NCI Technology Transfer Consortium

Karen Muszynski, PhD, Biological Resources Branch, Developmental Therapeutics Program, DCTD, NCI

Sherry Ansher, PhD, Regulatory Affairs Branch, Cancer Therapy Evaluation Program, DCTD, NCI

Malcom Smith, MD, PhD, Clinical Investigations Branch, Cancer Therapy Evaluation Program, DCTD, NCI

Jan Casadei, PhD, Regulatory Affairs Branch, Cancer Therapy Evaluation Program, DCTD, NCI

L. Mary Smith, PhD, United Therapeutics Corporation

Beverly Keseling, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research

Samir Shaban, MS, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research

Alice L. Yu, MD, PhD, University of California in San Diego Medical Center